3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
56
Fallopian Tube Neoplasms
25
Breast Neoplasms
18
Neoplasms
14
Carcinoma, Ovarian Epithelial
14
Multiple Myeloma
9
Neoplasm Metastasis
7
Triple Negative Breast Neoplasms
3
Recurrence
3
Peritoneal Neoplasms
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Cancer Recurrent
2
Liver Neoplasms
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Disease Progression
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Interventions
pembrolizumab
44
Carboplatin
28
Cisplatin
26
Paclitaxel
24
Bevacizumab
21
human papillomavirus vaccine, L1 type 16, 18
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
atezolizumab
11
Papillomavirus Vaccines
11
Nivolumab
10
tisotumab vedotin
8
Vaccines, Synthetic
8
Gemcitabine
8
Colposcopy
8
Topotecan
7
fludarabine
6
Vaccines
6
Injections
6
Cyclophosphamide
6
spartalizumab
5
balstilimab
5
Pemetrexed
5
Irinotecan
5
Fulvestrant
5
Docetaxel
5
zimberelimab
4
durvalumab
4
Vinorelbine
4
Ipilimumab
4
Interleukin-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Cervical Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled